Englander Institute for Precision Medicine
Found 835 results
Author Title Type [ Year(Asc)]
Filters: Corrigendum-whole-genome-and-transcriptome-analysis-pancreatic-acinar-cell-carcinoma is   [Clear All Filters]
2025
Nagar H, Diven MA, Rippon B, Barbieri CE, Hu JC, Scherr DS, Yadav P, Tshering L, Chandrasekhar S, Wolfe S et al..  2025.  A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution.. Eur Urol Oncol.
Akinsanya K, AlQuraishi M, Boija A, Chodera J, Cichońska A, Ghassemi M, Head M, Jin W, Kibbe WA, Krogan N et al..  2025.  Redefining druggable targets with artificial intelligence.. Nat Biotechnol.
Chukwu W, Lee S, Crane A, Zhang S, Webster S, Dakhama O, Mittra I, Rauert C, Imielinski M, Beroukhim R et al..  2025.  A sequence context-based approach for classifying tumor structural variants without paired normal samples.. Cell Rep Methods. :100991.
Kim J, Ravichandran H, Yoffe L, Bhinder B, Finos K, Singh A, Pua BB, Bates S, Huang BEmma, Rendeiro AF et al..  2025.  Simultaneous immunomodulation and epithelial-to-mesenchymal transition drives lung adenocarcinoma progression.. bioRxiv.
Lakin KS, Spivack J, Gordon JK, Zhang Y, Jannat-Khah D, Ravichandran H, Anandasabapathy N, Orange DE, Spiera RF.  2025.  Skin biopsies enhance prediction of clinical trajectory in diffuse cutaneous systemic sclerosis.. Arthritis Rheumatol.
Park J, De Gregorio R, Hissong E, Ozcelik E, Bartelo N, Dezem FSegato, Zhang L, Marção M, Chasteen H, Zheng Y et al..  2025.  The Spatial Atlas of Human Anatomy (SAHA): A Multimodal Subcellular-Resolution Reference Across Human Organs.. bioRxiv.
Foord C, Prjibelski AD, Hu W, Michielsen L, Vandelli A, Narykov O, Evans B, Hsu J, Belchikov N, Jarroux J et al..  2025.  A spatial long-read approach at near-single-cell resolution reveals developmental regulation of splicing and polyadenylation sites in distinct cortical layers and cell types.. Nat Commun. 16(1):8093.
Lv W, Zeng Y, Li C, Liang Y, Tao H, Zhu Y, Sui X, Li Y, Jiang S, Gao Q et al..  2025.  Spatial-Temporal Diversity of Extrachromosomal DNA Shapes Urothelial Carcinoma Evolution and the Tumor Immune Microenvironment.. Cancer Discov. :OF1-OF22.
Khani F, Beg S, Park K, Kawaguchi K, Chiu Y-L, Robinson BD, Lis R, Stack EC, Scherr DS, Rosenberg JE et al..  2025.  SPINK1 immunohistochemistry: An ancillary tool to diagnose urothelial carcinoma in situ and urothelial dysplasia.. Pathol Res Pract. 273:156148.
Al-Thani NM, Zaghlool SB, Toor SM, Abou-Samra ABadi, Suhre K, Albagha OME.  2025.  Subtyping of Type 2 Diabetes from a Large Middle Eastern Biobank: Implications for Precision Medicine.. Mol Metab. :102195.
Rubinelli L, Manzo OLaura, Sungho J, Del Gaudio I, Bareja R, Marino A, Palikhe S, Di Mauro V, Bucci M, Falcone DJ et al..  2025.  Suppression of endothelial ceramide de novo biosynthesis by Nogo-B contributes to cardiometabolic diseases.. Nat Commun. 16(1):1968.
Nuzzo PVitale, Rodrigues S, Ribeiro CFidalgo, Teixeira IFerrari, Fanelli GNicolo', Bleve S, Ravera F, Pakula H, Pederzoli F, Nanus DM et al..  2025.  Targeting Cancer Metabolism: Therapeutic Potential of the Fatty Acid Synthase (FASN) inhibitors.. Crit Rev Oncol Hematol. :104910.
Yost KE, Zhao Y, Hung KL, Zhu K, Xu D, M Corces R, Shams S, Louie BH, Sarmashghi S, Sundaram L et al..  2025.  Three-dimensional genome landscape of primary human cancers.. Nat Genet. 57(5):1189-1200.
Breves SL, Di Giammartino DCampigli, Nicholson J, Cirigliano S, Mahmood SRaza, Lee UJin, Martinez-Fundichely A, Jungverdorben J, Singhania R, Rajkumar S et al..  2025.  Three-dimensional regulatory hubs support oncogenic programs in glioblastoma.. Mol Cell.
Honigsberg R, Cruz T, Yoffe L, Tang MStephanie, Dicle O, Markowitz G, Michael M, Singh A, Altorki NK, Elemento O et al..  2025.  Tumor-specific draining lymph node CD8 T cells orchestrate an anti-tumor response to neoadjuvant PD-1 immune checkpoint blockade.. bioRxiv.
Nath S, Claridge S, Granados GLara, Assaad MAl, Park E, Cavallo J-A, Nuwere U, Ackon MEsi, De Boni L, Baker S et al..  2025.  Unlocking the therapeutic potential of rigosertib as a selective therapy for ovarian cancer.. Cell Rep Med. 6(7):102218.
Guevara D, Shin N, Boiko A, Valiev I, Elsaeed AG, Mosquera JMiguel, Assaad MAl, Manohar J, Sigouros M, Zaichikova A et al..  2025.  Unusual Presentation of Advanced Urothelial Cancer in a Young Patient.. Anticancer Res. 45(2):613-618.
Bonacci RE, McGill M, Le NThuy Anh, Barkarar M, Finnegan C, Wilson M, Ajagbe O, Udekwu CC, Gorski K, Manohar J et al..  2025.  Upregulation of the interferon-inducible antiviral gene RSAD2 in neuroendocrine prostate cancer via PVT1 exon 9 dependent and independent pathways.. J Biol Chem. :108370.
2024
Guillet S, Lazarov T, Jordan N, Boisson B, Tello M, Craddock B, Zhou T, Nishi C, Bareja R, Yang H et al..  2024.  ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis.. Elife. 13
Lira MCecilia, Vanpouille-Box C, Galluzzi L.  2024.  Adaptive inhibition of CGAS signaling by TREX1.. Trends Cancer. 10(3):177-179.
San Pedro JManuel Bra, Aranda F, Buqué A, Galluzzi L.  2024.  Animal models of disease: Achievements and challenges.. Methods Cell Biol. 188:xv-xxi.
Stenzl A, Armstrong AJ, Sboner A, Ghith J, Serfass L, Bland CS, Schijvenaars BJA, Sternberg CN.  2024.  Artificial INtelligence to Support Informed DEcision-making (INSIDE) for Improved Literature Analysis in Oncology.. Eur Urol Focus.
Desai P, Zhou Y, Grenet J, Handelman SK, Crispino CM, Tarbay LN, Whitsel EA, Roboz G, Barac A, Honigberg M et al..  2024.  Association of clonal hematopoiesis and mosaic chromosomal alterations with solid malignancy incidence and mortality.. Cancer.
De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C.  2024.  Author Correction: Cancer cell metabolism and antitumour immunity.. Nat Rev Immunol.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2024.  Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 15(1):225.